Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 19/20 | 1.00 |
| ▸ | CDK9 | P50750 | 19/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23125452 | 1.00 | CCNK (1.00) | CCNKCDK9CCNT1 | |
| SCHEMBL29474397 | 1.00 | CCNK (1.00) | CCNKCDK9CCNT1 | |
| SCHEMBL21747528 | 1.00 | CCNK (1.00) | CCNKCDK9CCNT1 | |
| SCHEMBL21747577 | 0.87 | CCNK (1.00) | CCNKCDK9CCNT1 | |
| SCHEMBL23125447 | 0.87 | CCNK (1.00) | CCNKCDK9CCNT1 | |
| SCHEMBL28408979 | 0.86 | CCNK (0.76) | CCNKCDK9CCNT1 | |
| Tambiciclib SCHEMBL23125424 | 0.85 | CDK9 (1.00) | CCNKCDK9CCNT1 | |
| Tambiciclib SCHEMBL23125451 | 0.85 | CDK9 (1.00) | CCNKCDK9CCNT1 | |
| Tambiciclib SCHEMBL21747523 | 0.85 | CDK9 (1.00) | CCNKCDK9CCNT1 | |
| Tambiciclib SCHEMBL21747508 | 0.85 | CDK9 (1.00) | CCNKCDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613737-B1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2021-03-23 | — | — | US | disclosed |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Shanghai Jiongshuo Pharmaceutical Technology Co., Ltd. (CN) | 2020-03-12 | — | — | US | disclosed |
| EP-3613737-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10952999-B2 | Inhibitor of cyclin-dependent kinase CDK9 | CDK9, CDK19, CDK1 | CCNK 14/4885CDK9 1/4885CCNT1 32/4885 |
| US-20200078343-A1 | NOVEL INHIBITOR OF CYCLIN-DEPENDENT KINASE CDK9 | CDK9, CDK19, CDKL1 | CCNK 17/4885CDK9 1/4885CCNT1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.